- Home
- RVPHW vs SKIN Comparison
RVPHW vs SKIN Comparison
Compare RVPHW & SKIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- SKIN
- Stock Information
- Founded
- RVPHW 2018
- SKIN 1997
- Country
- RVPHW United States
- SKIN United States
- Employees
- RVPHW 15
- SKIN N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- SKIN Package Goods/Cosmetics
- Sector
- RVPHW Health Care
- SKIN Consumer Discretionary
- Exchange
- RVPHW Nasdaq
- SKIN Nasdaq
- Market Cap
- RVPHW N/A
- SKIN N/A
- IPO Year
- RVPHW N/A
- SKIN N/A
- Fundamental
- Price
- RVPHW $0.06
- SKIN $0.99
- Analyst Decision
- RVPHW
- SKIN Hold
- Analyst Count
- RVPHW 0
- SKIN 5
- Target Price
- RVPHW N/A
- SKIN $2.50
- AVG Volume (30 Days)
- RVPHW 22.4K
- SKIN 710.3K
- Earning Date
- RVPHW 03-14-2025
- SKIN 05-08-2025
- Dividend Yield
- RVPHW N/A
- SKIN N/A
- EPS Growth
- RVPHW N/A
- SKIN N/A
- EPS
- RVPHW N/A
- SKIN N/A
- Revenue
- RVPHW N/A
- SKIN $334,294,000.00
- Revenue This Year
- RVPHW N/A
- SKIN N/A
- Revenue Next Year
- RVPHW N/A
- SKIN $7.18
- P/E Ratio
- RVPHW N/A
- SKIN N/A
- Revenue Growth
- RVPHW N/A
- SKIN N/A
- 52 Week Low
- RVPHW $0.13
- SKIN $0.78
- 52 Week High
- RVPHW $0.15
- SKIN $3.63
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- SKIN 42.40
- Support Level
- RVPHW N/A
- SKIN $0.89
- Resistance Level
- RVPHW N/A
- SKIN $1.04
- Average True Range (ATR)
- RVPHW 0.00
- SKIN 0.11
- MACD
- RVPHW 0.00
- SKIN 0.00
- Stochastic Oscillator
- RVPHW 0.00
- SKIN 46.73
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.